Trial shows no clear benefit from cannabis for patients with MS
BMJ 2003; 327 doi: https://doi.org/10.1136/bmj.327.7424.1128 (Published 13 November 2003) Cite this as: BMJ 2003;327:1128- Owen Dyer
- London
The three year CAMS (cannabis in multiple sclerosis) trial, involving more than 600 patients in the United Kingdom, has yielded no definitive verdict on whether the drug can ease the symptoms of multiple sclerosis. The study, funded by the Medical Research Council, was published in last week's issue of the Lancet (2003;362: 1517-26).
Fifteen weeks' treatment with oral capsules containing either whole cannabis extract or tetrahydrocannabinol (THC), the drug's principal active ingredient, did not produce a significant improvement in spasticity as measured by the widely used Ashworth scale.
But in face to face interviews, patients assigned …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.